142 related articles for article (PubMed ID: 18374395)
21. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of "blind placement" prostatic stent in patients with benign prostatic obstruction: a prospective study.
Kijvikai K; van Dijk M; Pes PL; Lertsithichai P; Wijkstra H; de la Rosette J
Urology; 2006 Nov; 68(5):1025-30. PubMed ID: 17113894
[TBL] [Abstract][Full Text] [Related]
23. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
24. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
25. Critical appraisal of the Spanner™ prostatic stent in the treatment of prostatic obstruction.
McKenzie P; Badlani G
Med Devices (Auckl); 2011; 4():27-33. PubMed ID: 22915927
[TBL] [Abstract][Full Text] [Related]
26. Improved quality of life and enhanced satisfaction after TURP: prospective 12-year follow-up study.
Mishriki SF; Grimsley SJ; Nabi G; Martindale A; Cohen NP
Urology; 2008 Aug; 72(2):322-6; discussion 326-8. PubMed ID: 18533236
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
[TBL] [Abstract][Full Text] [Related]
28. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
O'Leary MP; Wei JT; Roehrborn CG; Miner M;
BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
[TBL] [Abstract][Full Text] [Related]
29. Prostatic stents for the treatment of benign prostatic hyperplasia.
Vanderbrink BA; Rastinehad AR; Badlani GH
Curr Opin Urol; 2007 Jan; 17(1):1-6. PubMed ID: 17143103
[TBL] [Abstract][Full Text] [Related]
30. Benign prostatic obstruction and parkinson's disease--should transurethral resection of the prostate be avoided?
Roth B; Studer UE; Fowler CJ; Kessler TM
J Urol; 2009 May; 181(5):2209-13. PubMed ID: 19296974
[TBL] [Abstract][Full Text] [Related]
31. Transurethral microwave thermotherapy of the prostate--evaluation with MRI and analysis of parameters relevant to outcome.
Vesely S; Müller M; Knutson T; Peeker R; Hellström M; Dahlstrand C
Scand J Urol Nephrol; 2008; 42(1):53-8. PubMed ID: 18210336
[TBL] [Abstract][Full Text] [Related]
32. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
33. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
34. Transition zone index and bothersomeness of voiding symptoms as predictors of early unfavorable outcomes after transurethral resection of prostate.
Milonas D; Saferis V; Jievaltas M
Urol Int; 2008; 81(4):421-6. PubMed ID: 19077403
[TBL] [Abstract][Full Text] [Related]
35. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.
Rana Z; Cyr RA; Chen LN; Kim BS; Moures RA; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2014; 4():290. PubMed ID: 25374844
[TBL] [Abstract][Full Text] [Related]
36. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS.
Sexton CC; Coyne KS; Kopp ZS; Irwin DE; Milsom I; Aiyer LP; Tubaro A; Chapple CR; Wein AJ;
BJU Int; 2009 Apr; 103 Suppl 3():12-23. PubMed ID: 19302498
[TBL] [Abstract][Full Text] [Related]
37. [Assessment of the urinary status by self-administered questionnaires in men after radical prostatectomy-- comparison with the urination status of elderly women].
Taoka R; Shimada O; Kitamura Y; Okazoe H; Taniguchi S; Tsunemori H; Wu X; Inui M; Sugimoto M; Kakehi Y
Hinyokika Kiyo; 2008 Nov; 54(11):717-22. PubMed ID: 19068725
[TBL] [Abstract][Full Text] [Related]
38. Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.
Rana Z; Hong RL; Abugideiri M; McRae D; Cernica G; Mordkin R; Joel AB; Bernstein G; Nasr NM
Radiat Oncol; 2015 Aug; 10():182. PubMed ID: 26310244
[TBL] [Abstract][Full Text] [Related]
39. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
40. Clinical effectiveness of new stent design: randomized single-blind comparison of tail and double-pigtail stents.
Dunn MD; Portis AJ; Kahn SA; Yan Y; Shalhav AL; Elbahnasy AM; Bercowsky E; Hoenig DM; Wolf JS; McDougall EM; Clayman RV
J Endourol; 2000 Mar; 14(2):195-202. PubMed ID: 10772515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
